Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Artificial Intelligence Diagnostic Imaging Cancer

Paige Obtains NHSx Award Allowing It To Launch AI Prostate Test

  • News

Executive Summary

NHSx has awarded Paige an undisclosed sum of money to support development of its AI-powered prostate cancer detection tool in clinical settings in the UK.

You may also be interested in...



Upgraded Paige Suite Gains CE-IVD and UKCA Marks

Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.

Minute Insight: Agendia Collaborates With Illumina And Brazilian Health Care Providers

The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.

Another Set Of Eyes: US FDA Authorizes AI Software To Spot Prostate Cancer

The Paige Prostate is a first-of-its-kind digital prostate imaging analysis software that can act as an extra pair of eyes to help pathologists spot cancer cells.

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Artificial Intelligence Diagnostic Imaging Cancer
Latest Headlines

Bill Covering Breakthrough Products ‘Step In The Wrong Direction,’ Researchers Say

Commission Text Clarifying Timelines For Annex XVI Devices May Leave Companies Dazed

Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early

Minute Insight: Enovis Buys Lima To Create Billion-Dollar Recon Business

See All
UsernamePublicRestriction

Register

MT144151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By